Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Ponatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 84,623Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fangzhou Launches Otsuka's Ponatinib Leukemia Drug on Platform
    Fangzhou Launches Otsuka's Ponatinib Leukemia Drug on Platform

    05 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fangzhou-launches-otsukas-third-generation-leukemia-drug-ponatinib-on-its-platform-302446583.html

    PR NEWSWIRE
    05 May 2025
    Share Share
    Olverembatinib Overcomes CML Resistance, Well Tolerated in Report
    Olverembatinib Overcomes CML Resistance, Well Tolerated in Report

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olverembatinib-surmounts-ponatinib-and-asciminib-resistance-and-is-well-tolerated-in-patients-with-cml-and-ph-all-new-report-in-jama-oncology-302313802.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    Ponatinib HCL: A Targeted Therapy for CML and Ph+ ALL
    Ponatinib HCL: A Targeted Therapy for CML and Ph+ ALL

    11 Jun 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/ponatinib-hcl-a-targeted-therapy-for-cml-and-ph-all

    PRESS RELEASE
    11 Jun 2024
    Share Share
    Ponatinib Hydrochloride Balancing Efficacy & Safety in Leukemia
    Ponatinib Hydrochloride Balancing Efficacy & Safety in Leukemia

    29 Apr 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/ponatinib-hydrochloride-balancing-efficacy-and-safety-in-leukemia-treatment

    PRESS RELEASE
    29 Apr 2024
    Share Share
    Takeda's Iclusig wins first-line FDA nod to treat Ph+ALL
    Takeda's Iclusig wins first-line FDA nod to treat Ph+ALL

    20 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercepharma.com/pharma/fda-moves-takedas-iclusig-first-line-use-rare-philadelphia-chromosome-all

    FIERCE BIOTECH
    20 Mar 2024
    Share Share
    Takeda Announces U.S. FDA Approval of sNDA) for ICLUSIG® (ponatinib)
    Takeda Announces U.S. FDA Approval of sNDA) for ICLUSIG® (ponatinib)

    19 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240319911372/en

    BUSINESSWIRE
    19 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.